S100A8/A9 is associated with estrogen receptor loss in breast cancer

Bao,Yi; Wang,Antao; Mo,Juanfen

doi:10.3892/ol.2016.4134

S100A8/A9 is associated with estrogen receptor loss in breast cancer

Authors:
- Yi Bao
- Antao Wang
- Juanfen Mo
View Affiliations

Affiliations: Basic and Translational Cancer Research Laboratory, The Second Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China
Published online on: January 20, 2016 https://doi.org/10.3892/ol.2016.4134
Pages: 1936-1942

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

S100A8 and S100A9 are calcium‑binding proteins that are secreted primarily by granulocytes and monocytes, and are upregulated during the inflammatory response. S100A8 and S100A9 have been identified to be expressed by epithelial cells involved in malignancy. In the present study, the transcriptional levels of S100A8 and S100A9 were investigated in various subtypes of breast cancer (BC), and the correlation with estrogen receptor 1 (ESR1) and GATA binding protein 3 (GATA3) gene expression was evaluated using microarray datasets. The expression of S100A8 and S100A9 in BC cells was assessed by reverse transcription‑polymerase chain reaction (RT‑PCR). The regulation of ESR1 and GATA3 by administration of recombinant S100A8/A9 was examined in the BC MCF‑7 cell line using quantitative (q)PCR. The association between S100A8 and S100A9 and overall survival (OS) was investigated in GeneChip® data of BC. The expression levels of S100A8 and S100A9 were higher in human epidermal growth factor receptor 2 (Her2)‑amplified and basal‑like BC. The messenger (m)RNA levels of S100A8 and S100A9 were inversely correlated with ESR1 and GATA3 expression. S100A8/A9 induced a 10‑fold decrease in the mRNA levels of ESR1 in MCF‑7 cells. Poor OS was associated with high expression levels of S100A9, but not with high expression levels of S100A8 in BC. In conclusion, strong expression and secretion of S100A8/A9 may be associated with the loss of estrogen receptor in BC, and may be involved in the poor prognosis of Her2+/basal‑like subtypes of BC.

View Figures

View References

1	Hessian PA, Edgeworth J and Hogg N: MRP-8 and MRP-14, two abundant Ca⁽²⁺⁾-binding proteins of neutrophils and monocytes. J Leukoc Biol. 53:197–204. 1993.PubMed/NCBI
2	Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S and Srikrishna G: Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 181:4666–4675. 2008. View Article : Google Scholar : PubMed/NCBI
3	Heizmann CW, Fritz G and Schäfer BW: S100 proteins: Structure, functions and pathology. Front Biosci. 7:d1356–d1368. 2002. View Article : Google Scholar : PubMed/NCBI
4	Srikrishna G: S100A8 and S100A9: New insights into their roles in malignancy. J Innate Immun. 4:31–40. 2012. View Article : Google Scholar : PubMed/NCBI
5	Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, Horwood N and Nanchahal J: Alarmins: Awaiting a clinical response. J Clin Invest. 122:2711–2719. 2012. View Article : Google Scholar : PubMed/NCBI
6	Vogl T, Eisenblätter M, Völler T, Zenker S, Hermann S, van Lent P, Faust A, Geyer C, Petersen B, Roebrock K, et al: Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity. Nat Commun. 5:45932014. View Article : Google Scholar : PubMed/NCBI
7	Wang L, Chang EW, Wong SC, Ong SM, Chong DQ and Ling KL: Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 190:794–804. 2013. View Article : Google Scholar : PubMed/NCBI
8	Reis-Filho JS and Pusztai L: Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet. 378:1812–1823. 2011. View Article : Google Scholar : PubMed/NCBI
9	Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, et al: Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 39:655–660. 2007. View Article : Google Scholar : PubMed/NCBI
10	Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
11	Sonnenblick A, Fumagalli D, Sotiriou C and Piccart M: Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up? Cancer Treat Rev. 40:1089–1095. 2014. View Article : Google Scholar : PubMed/NCBI
12	Gajria D and Chandarlapaty S: HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
13	Dey N, Smith BR and Leyland-Jones B: Targeting basal-like breast cancers. Curr Drug Targets. 13:1510–1524. 2012. View Article : Google Scholar : PubMed/NCBI
14	Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A and Kim HR: Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res. 6:1544–1553. 2008. View Article : Google Scholar : PubMed/NCBI
15	Yin C, Li H, Zhang B, Liu Y, Lu G, Lu S, Sun L, Qi Y, Li X and Chen W: RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition. Breast Cancer Res Treat. 142:297–309. 2013. View Article : Google Scholar : PubMed/NCBI
16	van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
17	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
18	Campbell MJ and Machin D: Medical Statistics: A Commonsense Approach (3rd). London, UK: Wiley. 1999.
19	Kerdivel G, Flouriot G and Pakdel F: Modulation of estrogen receptor alpha activity and expression during breast cancer progression. Vitam Horm. 93:135–160. 2013. View Article : Google Scholar : PubMed/NCBI
20	Miyoshi Y, Murase K, Saito M, Imamura M and Oh K: Mechanisms of estrogen receptor-α upregulation in breast cancers. Med Mol Morphol. 43:193–196. 2010. View Article : Google Scholar : PubMed/NCBI
21	Mueller SO, Clark JA, Myers PH and Korach KS: Mammary gland development in adult mice requires epithelial and stromal estrogen receptor α. Endocrinology. 143:2357–2365. 2002. View Article : Google Scholar : PubMed/NCBI
22	Fang SH, Chen Y and Weigel RJ: GATA-3 as a marker of hormone response in breast cancer. J Surg Res. 157:290–295. 2009. View Article : Google Scholar : PubMed/NCBI
23	Kouros-Mehr H, Slorach EM, Sternlicht MD and Werb Z: GATA3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 127:1041–1055. 2006. View Article : Google Scholar : PubMed/NCBI
24	Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Sahin A, Katz R, et al: Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Horm Cancer. 1:21–33. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kouros-Mehr H, Kim JW, Bechis SK and Werb Z: GATA3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol. 20:164–170. 2008. View Article : Google Scholar : PubMed/NCBI
26	Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS and Brown M: Positive cross-regulatory loop ties GATA3 to estrogen receptor alpha expression in breast cancer. Cancer Res. 67:6477–6483. 2007. View Article : Google Scholar : PubMed/NCBI
27	Yan W, Cao QJ, Arenas RB, Bentley B and Shao R: GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem. 285:14042–14051. 2010. View Article : Google Scholar : PubMed/NCBI
28	Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Henderson R, Robinson MJ and Hogg N: Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol. 23:2564–2576. 2003. View Article : Google Scholar : PubMed/NCBI
29	Hoch RV, Thompson DA, Baker RJ and Weigel RJ: GATA3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 84:122–128. 1999. View Article : Google Scholar : PubMed/NCBI
30	Gebhardt C, Németh J, Angel P and Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 72:1622–1631. 2006. View Article : Google Scholar : PubMed/NCBI
31	Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature. 411:375–379. 2001. View Article : Google Scholar : PubMed/NCBI
32	Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ: The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138:105–115. 2013. View Article : Google Scholar : PubMed/NCBI
33	Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, et al: A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
34	Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ and Perou CM: Concordance among gene-expression- based predictors for breast cancer. N Engl J Med. 355:560–569. 2006. View Article : Google Scholar : PubMed/NCBI